- Report
- March 2021
- 330 Pages
Global
From €4276EUR$4,799USD£3,709GBP
- Report
- June 2023
- 116 Pages
Global
From €4010EUR$4,500USD£3,478GBP
- Report
- February 2024
- 182 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Report
- May 2024
- 133 Pages
Global
From €5791EUR$6,499USD£5,023GBP
- Report
- January 2023
- 116 Pages
Global
From €3408EUR$3,825USD£2,956GBP
€4010EUR$4,500USD£3,478GBP
- Report
- May 2024
- 160 Pages
Global
From €4428EUR$4,969USD£3,840GBP
- Report
- February 2024
- 180 Pages
Global
From €4428EUR$4,969USD£3,840GBP
- Report
- February 2024
- 108 Pages
Global
From €3500EUR$4,208USD£3,142GBP
The Estrogen Receptor (ER) market is a segment of the Endocrine and Metabolic Disorders Drugs market. ER drugs are used to treat a variety of conditions, including menopausal symptoms, osteoporosis, and breast cancer. ER drugs work by binding to the estrogen receptor, which is found in many tissues throughout the body. This binding triggers a cascade of events that can lead to the desired therapeutic effect. ER drugs are typically administered orally, as a topical cream, or as an injection.
ER drugs are typically prescribed to postmenopausal women, as well as to men with certain conditions. The market for ER drugs is expected to grow in the coming years, driven by an aging population and increasing awareness of the importance of hormone therapy.
Some companies in the ER market include Pfizer, Novartis, Merck, and AstraZeneca. Show Less Read more